Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow.

Cancer discovery - 1 Sept 2014

Gibbons Don L, Byers Lauren Averett

Abstract excerpt

SUMMARY: Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Resistance, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 25185188
DOI: 10.1158/2159-8290.CD-14-0791
PMCID: PMC4990388

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow.PMID 25185188Read ↗

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.Semantic proximity Read ↗

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision MedicineSemantic proximity Read ↗

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.Semantic proximity Read ↗

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.Semantic proximity Read ↗

Emerging combination therapies to overcome resistance in EGFR-driven tumors.Semantic proximity Read ↗

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.Semantic proximity Read ↗

Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLCSemantic proximity Read ↗

An early look at selective RET inhibitor resistance: new challenges and opportunities.Semantic proximity Read ↗

A vanishing act: the incredible erlotinib.Semantic proximity Read ↗

Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?Semantic proximity Read ↗

Resistance to tyrosine kinase inhibitors: calling on extra forces.Semantic proximity Read ↗

Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.